-
Something wrong with this record ?
Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation
H. Hnátová, K. Fulínová, B. Řiháková, J. Bonaventura, J. Veselka
Status not-indexed Language English Country Ireland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2015
PubMed Central
from 2014
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2014-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2015
- Publication type
- Journal Article MeSH
BACKGROUND: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. METHODS: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. RESULTS: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). CONCLUSIONS: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022387
- 003
- CZ-PrNML
- 005
- 20240116163025.0
- 007
- ta
- 008
- 240105s2023 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcha.2023.101317 $2 doi
- 035 __
- $a (PubMed)38126007
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Hnátová, Hana $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 245 10
- $a Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation / $c H. Hnátová, K. Fulínová, B. Řiháková, J. Bonaventura, J. Veselka
- 520 9_
- $a BACKGROUND: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. METHODS: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. RESULTS: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). CONCLUSIONS: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Fulínová, Klára $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Řiháková, Barbora $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Bonaventura, Jiří $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Veselka, Josef $u Department of Cardiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00198717 $t International journal of cardiology. Heart & vasculature $x 2352-9067 $g Roč. 49, č. - (2023), s. 101317
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38126007 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240105 $b ABA008
- 991 __
- $a 20240116163021 $b ABA008
- 999 __
- $a ok $b bmc $g 2036263 $s 1208832
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 49 $c - $d 101317 $e 20231202 $i 2352-9067 $m International journal of cardiology Heart & vasculature $n Int J Cardiol Heart Vasc $x MED00198717
- LZP __
- $a Pubmed-20240105